Skip to main content
Retour
Watch Compare

Indaptus Therapeutics, Inc.

Qualité des données : 83%
INDP
NASDAQ Manufacturing Chemicals
2,11 €
▲ 0,26 € (14,05%)
Cap. Boursière: 4,15 M
Prix
1,85 €
Cap. Boursière
4,15 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—

Quick Summary

Points Clés

Negative free cash flow of -14,82 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-1421,98%
En dessous de la moyenne du secteur (-54,47%)
ROIC-1068,66%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio2,88
Interest CoverageN/A

Valorisation

PE (TTM)
-0,20
Au-dessus de la moyenne du secteur (-1,49)
P/B Ratio0,90
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1385 pairs)
Métrique Action Médiane du Secteur
P/E -0,2 -1,5
P/B 0,9 1,6
ROE % -1422,0 -54,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,9
D/E — 0,3

Objectif de Cours des Analystes

1 analyste
Hold
Actuel
2,11 €
+373.9%
Objectif
10,00 €
10,00 €
10,00 €
10,00 €
Prévisions
BPA Prévisionnel -4,48 €
CA Est. 0,0

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2027 -4,48 €
-4,48 € – -4,48 €
 0,0 1
FY2026 -6,43 €
-6,43 € – -6,43 €
 0,0 1

Surprises de Résultats

Derniers 4 trimestres
Trimestre BPA Est. BPA Réel Surprise
Q42025 -4,36 € -9,19 € -110,8%
Q32025 -4,17 € -2,98 € +28,5%
Q22025 -9,24 € -9,09 € +1,6%
Q12025 -5,04 € -8,96 € -77,8%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -20,85 M
ROE -1421,98% ROA -304,83%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -14,82 M
ROIC -1068,66% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2,88
Interest Coverage N/A Asset Turnover N/A
Working Capital 4,20 M Tangible Book Value 4,61 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,20 Forward P/E N/A
P/B Ratio 0,90 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -357,33%
Market Cap 4,15 M Enterprise Value -1,68 M
Per Share
EPS (Diluted TTM) -21,58 Revenue / Share N/A
FCF / Share -6,61 OCF / Share -6,61
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 71,10%
SBC-Adj. FCF -15,84 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -20,85 M -15,02 M -15,42 M -14,32 M -7,71 M
EPS (Diluted) -21,58 -1,61 -1,83 — —
Gross Profit — — — — —
Operating Income -19,83 M -15,37 M -16,38 M -14,91 M -7,73 M
EBITDA — — — — —
R&D Expenses 9,34 M 7,25 M 7,62 M 6,32 M 2,52 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — — — — —
Income Tax 1 716,0 1 700,0 2 450,0 30,0 1 650,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 9,31 M 7,34 M 14,92 M 28,06 M 40,58 M
Total Liabilities — 3,39 M 2,85 M 3,43 M 4,68 M
Shareholders' Equity 3,15 M 3,94 M 12,08 M 24,63 M 35,90 M
Total Debt — — — — —
Cash & Equivalents 8,51 M 5,79 M 13,36 M 9,63 M 39,13 M
Current Assets 9,31 M 6,62 M 14,00 M 27,24 M 40,39 M
Current Liabilities 6,16 M 3,39 M 2,77 M 3,43 M 4,60 M